uniQure NV
Закрыт
46.16 -4.15
Обзор
Изменение цены акций
24 ч
Мин.
45.71
Макс.
47.1
Доход | -16M -54M |
|---|---|
Продажи | -2M 3.6M |
Прибыль на акцию | -0.73 |
Рентабельность продаж | -1,502.948 |
Сотрудники | 221 |
EBITDA | 13M -36M |
Рекомендации | Активная покупка |
|---|---|
Прогноз на 12 месяцев | +17.87% upside |
Следующий отчет о доходах | 28 июл. 2026 г. |
|---|
Рыночная капитализация | 454M 1.8B |
|---|---|
Предыдущая цена открытия | 50.31 |
Предыдущая цена закрытия | 46.16 |
uniQure NV График
Прошлые результаты не являются надежным индикатором будущих результатов.
О компании uniQure NV
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
